---
title: "野村將石藥集團的目標價從 9.11 港元調整至 12.04 港元，並維持買入評級"
description: "野村將石藥集團的目標價從 9.11 港元上調至 12.04 港元，維持 “買入” 評級"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/276056763.md"
published_at: "2026-02-16T12:30:47.000Z"
---

# 野村將石藥集團的目標價從 9.11 港元調整至 12.04 港元，並維持買入評級

> 野村將石藥集團的目標價從 9.11 港元上調至 12.04 港元，維持 “買入” 評級

### Related Stocks

- [01093.HK - 石藥集團](https://longbridge.com/zh-HK/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |
| CSPC Pharma Unit Files Application with HKEX for Proposed H-Share Listing | CSPC Pharma Unit Files Application with HKEX for Proposed H-Share Listing | [Link](https://longbridge.com/zh-HK/news/269327436.md) |
| Essent Group raises dividend by 12.9% to 0.35 | Essent Group raises dividend by 12.9% to 0.35 | [Link](https://longbridge.com/zh-HK/news/275908049.md) |
| CSPC Pharma Gets China Nod for Multiple Drug Trials | CSPC Pharma Gets China Nod for Multiple Drug Trials | [Link](https://longbridge.com/zh-HK/news/270994613.md) |
| CICC Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF) | CICC has reaffirmed its Buy rating for CSPC Pharmaceutical Group (CHJTF) with a price target of HK$12.00. Additionally,  | [Link](https://longbridge.com/zh-HK/news/274393834.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。